Epidemiology

International Doctors present their findings via video on the NASH and NAFLD epidemic on this free-to-access NASH content library.

Clinical Chemistry in NAFLD Part 2 – Biomarkers and Hepatic Steatosis and NASH

Clinical Chemistry in NAFLD Part 2 – Biomarkers, Hepatic Steatosis and NASH

Discover how key biomarkers like Fatty Liver Index and SteatoTest are transforming NAFLD diagnosis and management. Delve into the disease's pathophysiology, the impact of obesity and insulin resistance, and the advancements in specialized liver tests.
View More ⏩Clinical Chemistry in NAFLD Part 2 – Biomarkers, Hepatic Steatosis and NASH
5Th Global Nash Congress

5Th Global Nash Congress

This slides set presents a detailed review of vascular alterations in non-alcoholic steatohepatitis (NASH) and NASH cirrhosis delivered by Professor Francque, MD, PhD. He highlights that non-fibrotic non-alcoholic fatty liver disease (NAFLD) is accompanied by a significant rise in portal pressure. Professor Francque, also explains the effects of intrahepatic vascular resistance increase in NAFLD. To the clinicians, he provides various patient studies, statistics and clinical data on the subject.
View More ⏩5Th Global Nash Congress
Prof. Sven Francque

From number-one liver disease to multi-system disease: NASH, a major unmet clinical need

In this opening talk of the 1st PanNASH webinar, Prof. Sven Francque (Belgium), one of the PanNASH editors, explains how NASH, the number-one liver disease, is part of a multisystem disease. He also sheds light on the etiology of this disease, its epidemiology, symptoms and consequences.
View More ⏩From number-one liver disease to multi-system disease: NASH, a major unmet clinical need
Prof.-Manuel-Romero-Gomez

Imaging biomarkers in NAFLD: Could they avoid liver biopsy

There is a need for new biomarkers that allow the detection and quantification of liver diseases supported on the measurement of fat, iron, fibrosis, inflammation. Dr Romero-Gomez presents a state-of-the-art video on imaging biomarkers with the pros and cons for each technology. For daily practice, he also suggests a diagnosis algorithm
View More ⏩Imaging biomarkers in NAFLD: Could they avoid liver biopsy

NAFLD: a hegemonic disease by Prof. S. Francque

In this Expert perspective video, Prof Sven Francque explains how to make the distinction between NAFL and NASH. This is important even though in clinical practice there is a continuum between the two. In the pathophysiology of NASH there is a complex interplay between different organs. Adipose tissue dysfunction is an important driver of disease.
View More ⏩NAFLD: a hegemonic disease by Prof. S. Francque

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES